Latest revenue
$0
as of 2026-01-31
Latest net income
$-2.0M
as of 2026-01-31
Net margin
—
as of 2026-01-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $6.3M
- Enterprise value
- $6.3M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $6.47
- 52-wk low
- $1.77
- Beta
- —
- Shares out
- 3.2M
5-year trend
dashed bar = fiscal Q4 derived from 10-K annual − Q1 − Q2 − Q3 (SEC requires only three 10-Qs per year).
What this company does
Item 1. Business. Company Overview We are a medical technology company focused on applying innovative AI-based technology to an ECG, also known as an “EKG,” to expand and improve an ECG’s clinical usefulness. Our objective is to make an ECG a far more valuable cardiac screening tool by expanding its clinical capability to detect a broader range of heart disease conditions through the development of AI-based ECG algorithms (“AI-ECG”). We are seeking to provide AI-ECG solutions in any care setting worldwide in a manner that best suits different providers, either via our cloud-based application that can receive an upload from one of the millions of ECG devices currently in clinical use or via…
AI summary unavailable — showing raw filing excerpt
Generated from HSCS's filing dated 2025-07-24
Key risks
Item 1A. Risk Factors Our business is subject to numerous risks, as more fully described below in this "Risk Factors" section. The following is a summary of the most significant risks and uncertainties that we believe could adversely affect our business, financial condition, and results of operations. In addition to the following summary, you should read the other information set forth below in this “Risk Factors” section before you invest in our securities. In particular, our risks include, but are not limited to, the following: Risks Related to Our Financial Condition and Capital Requirements: •We have a limited operating history and we have incurred significant operating losses since our…
AI summary unavailable — showing raw filing excerpt
Generated from HSCS's filing dated 2025-07-24
Profitability
Gross margin
56.8%
15.6%Operating margin
-192013.1%
466.4%Net margin
-201499.5%
467.4%Return on equity
-4272.2%
49.1%Return on assets
-207.6%
198.6%Leverage
Debt / equity
19.58×
51.3%Long-term debt / equity
0.00×
100.0%Debt / assets
95.1%
2.5%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-01-31 | $0 | — | $-2.0M | +21.7% | — |
Q4 2025 2025-10-31 | $2.4K | — | $-2.4M | -12.9% | -97179.4% |
Q3 2025 2025-07-31 | $1.9K | — | $-2.1M | -0.2% | -108157.6% |
Q2 2025 2025-04-30 | — | — | $-2.1M | -13.4% | — |
Q1 2025 2025-01-31 | $0 | -100.0% | $-2.5M | -54.3% | — |
Q4 2024 2024-10-31 | — | — | $-2.1M | -19.1% | — |
Q3 2024 2024-07-31 | — | — | $-2.1M | -50.1% | — |
Q2 2024 2024-04-30 | — | — | $-1.8M | — | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Orthopedic, Prosthetic & Surgical Appliances & Supplies · SIC 3842
Your notes
Keep private notes on HSCS — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$15.6K
Net activity
−$15.6K
Distinct insiders
1
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns HSCS
Institutional value
$138.7K
Total shares held
55.2K
Distinct holders
4
-5 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | TFB Advisors LLC | 29.7K | $74.8K | +0 (+0.0%) | No change |
| 2 | Astoria Strategic Wealth, Inc. | 18.9K | $47.6K | +0 (+0.0%) | No change |
| 3 | UBS Group AG | 6.5K | $16.3K | +508 (+8.5%) | Added |
| 4 | WELLS FARGO & COMPANY/MN | 25 | $63 | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once HSCS's latest filing finishes processing.